Harvey Samowitz, MD
Urology · Hallandale Beach, FLNPI 1477518082
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,451 of the $9,823 with a category attached, or 65.7%. It is spread thinly across 37 manufacturers, the largest accounting for just 15.4%. Reporting peaked in 2019 at $2,298 and has fallen 96.6% since, to $77 in 2025.
Across 263 payments — averaging $37.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- Neotract Inc.$1K
- Johnson & Johnson$1K
- Axonics, Inc.$1K
- Myriad Genetic Laboratories, Inc.$765
- Valencia Technologies Corporation$683
- plus $3K from 31 others
Across 127 payments — averaging $28,534 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.2M
- Evofem Biosciences, Inc.$1M
- IBSA Institut Biochimique SA$322K
- AbbVie$27K
What the payments were for
- Travel & lodging$3,11932%
- Food & beverage$6,45166%
- Education$2543%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 28 | $1,516 |
| Neotract Inc. | 16 | $1,446 |
| Johnson & Johnson(3 entities) | 69 | $1,291 |
| Axonics, Inc. | 26 | $1,240 |
| Myriad Genetic Laboratories, Inc. | 15 | $765 |
| Valencia Technologies Corporation | 3 | $683 |
| Astellas Pharma US Inc | 27 | $637 |
| AbbVie(2 entities) | 14 | $416 |
| Endo Pharmaceuticals Inc. | 11 | $229 |
| Boston Scientific | 4 | $165 |
| Antares Pharma, Inc. | 5 | $137 |
| Olympus America Inc. | 2 | $134 |
| Uromedica, Incorporated | 1 | $130 |
| Rochester Medical Corporation | 4 | $122 |
| Medtronic | 3 | $112 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $74 |
| Halozyme Inc | 3 | $68 |
| Caldera Medical, Inc | 1 | $63 |
| Mission Pharmacal Company | 2 | $62 |
| Pfizer | 3 | $55 |
| Teleflex LLC | 2 | $51 |
| Clarus Therapeutics Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| Tolmar, Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Merck | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Bayer | 1 | $27 |
| AstraZeneca | 1 | $21 |
| Novartis | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $17 |
| Bluewind Medical | 1 | $15 |
| Amgen | 1 | $15 |
| Bard Access Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,143
- TITAN$1,075
- eCoin Device Kit$611
- Axonics r-SNM System$594
- Bulkamid$465
- ProACT$130
- Lupron Depot$125
- Dornier MedTech$111
- Erleada$111
How this compares
$9,823 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 21 | $313,458 |
| MyrbetriqMirabegron | 95 | $77,947 |
| GemtesaVibegron | 62 | $46,148 |
| Methenamine Hippurate | 81 | $6,878 |
| Tamsulosin Hcl | 260 | $3,895 |
| Solifenacin Succinate | 57 | $3,121 |
| Estradiol | 30 | $2,002 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,613 |
| Dutasteride | 56 | $1,603 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 68 | $1,124 |
| Trospium Chloride | 14 | $622 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 36 | $590 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 31 | $389 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $386 |
| Oxybutynin Chloride | 20 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,291 | $313,45821 claims |
| Astellas Pharma US IncMyrbetriq | $637 | $77,94795 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $43 | $46,14862 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Hallandale Beach
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.